NCT05027776View on ClinicalTrials.gov

Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years

PHASE3RecruitingINTERVENTIONAL
Enrollment

1,348

Participants

Timeline

Start Date

September 15, 2021

Primary Completion Date

November 22, 2023

Study Completion Date

September 29, 2026

Conditions
HPV InfectionsCervical Cancer Stage IIaVaginal CancerGenital WartCIN1CIN2CIN3
Interventions
BIOLOGICAL

2-doses Group among 9-14 years

Subjects were planned to receive two doses of the study vaccine administered intramuscularly according to a 0, 6 month vaccination schedule.

BIOLOGICAL

3-doses Group among 9-19 years

Subjects were planned to receive three doses of the study vaccine administered intramuscularly according to a 0, 2, 6 month vaccination schedule.

BIOLOGICAL

3-doses Group among 20-26 years

Subjects were planned to receive three doses of the study vaccine administered intramuscularly according to a 0, 2, 6 month vaccination schedule.

Trial Locations (1)

Unknown

RECRUITING

Center for Disease Control and Prevention, Mianyang

All Listed Sponsors
collaborator

Chongqing Bovax Biopharmaceutical Co., Ltd.

INDUSTRY

lead

Shanghai Bovax Biotechnology Co., Ltd.

INDUSTRY